|
|
Blood, 15 June 2006, Vol. 107, No. 12, pp. 4606-4613.
Prepublished online as a Blood First Edition Paper on February 9, 2006; DOI 10.1182/blood-2005-06-2448.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
Gita V. Massey,
Alvin Zipursky,
Myron N. Chang,
John J. Doyle,
Suhail Nasim,
Jeffrey W. Taub,
Yaddanapudi Ravindranath,
Gary Dahl, and
Howard J. Weinstein
From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston.
A unique transient leukemia (TL) has been described in newborns with Down syndrome (DS; or trisomy 21 mosaics). This leukemia has a high incidence of spontaneous remission; however, early death and subsequent development of acute megakaryoblastic leukemia (AMKL) have been reported. We prospectively evaluated 48 infants with DS and TL to determine the natural history and biologic characteristics of this disease, identify the clinical characteristics associated with early death or subsequent leukemia, and assess the incidence of subsequent leukemia. Blast cells associated with TL in DS infants exhibited FAB M7 morphology and phenotype. Most infants (74%) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells. Most children were able to spontaneously clear peripheral blasts (89%), normalize blood counts (74%), and maintain a complete remission (64%). Early death occurred in 17% of infants and was significantly correlated with higher white blood cell count at diagnosis (P < .001), increased bilirubin and liver enzymes (P < .005), and a failure to normalize the blood count (P = .001). Recurrence of leukemia occurred in 19% of infants at a mean of 20 months. Development of leukemia was significantly correlated with karyotypic abnormalities in addition to trisomy 21 (P = .037). Ongoing collaborative clinical studies are needed to determine the optimal role of chemotherapy for infants at risk for increased mortality or disease recurrence and to further the knowledge of the unique biologic features of this TL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Two tales of infant leukemia
- Ching-Hon Pui
Blood 2006 107: 4576-4577.
[Full Text]
[PDF]
Related Letter in Blood Online:
-
Use of the International System for Human Cytogenetic Nomenclature (ISCN)
- Juan Ramon Gonzalez Garcia, Juan Pablo Meza-Espinoza, Gita Vasers Massey, Howard J. Weinstein, and Alvin Zipursky
Blood 2006 108: 3952-3953.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Malinge, S. Izraeli, and J. D. Crispino
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Blood,
March 19, 2009;
113(12):
2619 - 2628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Rabin and J. A. Whitlock
Malignancy in Children with Trisomy 21
Oncologist,
February 1, 2009;
14(2):
164 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Tunstall-Pedoe, A. Roy, A. Karadimitris, J. de la Fuente, N. M. Fisk, P. Bennett, A. Norton, P. Vyas, and I. Roberts
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations
Blood,
December 1, 2008;
112(12):
4507 - 4511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Chou, J. B. Opalinska, Y. Yao, M. A. Fernandes, A. Kalota, J. S. J. Brooks, J. K. Choi, A. M. Gewirtz, G.-a. Danet-Desnoyers, R. L. Nemiroff, et al.
Trisomy 21 enhances human fetal erythro-megakaryocytic development
Blood,
December 1, 2008;
112(12):
4503 - 4506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-H. Klusmann, U. Creutzig, M. Zimmermann, M. Dworzak, N. Jorch, C. Langebrake, A. Pekrun, K. Macakova-Reinhardt, and D. Reinhardt
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
Blood,
March 15, 2008;
111(6):
2991 - 2998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. O'Brien, J. W. Taub, M. N. Chang, G. V. Massey, K. C. Stine, S. C. Raimondi, D. Becton, Y. Ravindranath, and G. V. Dahl
Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421
J. Clin. Oncol.,
January 20, 2008;
26(3):
414 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica,
November 1, 2007;
92(11):
1519 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Webb, I. Roberts, and P. Vyas
Haematology of Down syndrome
Arch. Dis. Child. Fetal Neonatal Ed.,
November 1, 2007;
92(6):
F503 - F507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Pine, Q. Guo, C. Yin, S. Jayabose, C. M. Druschel, and C. Sandoval
Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome
Blood,
September 15, 2007;
110(6):
2128 - 2131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tober, A. Koniski, K. E. McGrath, R. Vemishetti, R. Emerson, K. K. L. de Mesy-Bentley, R. Waugh, and J. Palis
The megakaryocyte lineage originates from hemangioblast precursors and is an integral component both of primitive and of definitive hematopoiesis
Blood,
February 15, 2007;
109(4):
1433 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Gonzalez Garcia, J. P. Meza-Espinoza, G. V. Massey, H. J. Weinstein, and A. Zipursky
Use of the International System for Human Cytogenetic Nomenclature (ISCN).
Blood,
December 15, 2006;
108(12):
3952 - 3953.
[Full Text]
[PDF]
|
|
|
|
|
